Promising antidiabetic drug

We have started an interesting study with a promising antidiabetic drug. The drug is designed in the form of prolonged-action tablets, which action leads to increased insulin secretion. It is an innovative drug that is in the first phase of research when it is first used in humans. The first drug administrations are behind us, we continue with the next doses. We plan to complete 1 part of SAD (single ascending dose) at the end of July.

More and more people are suffering from type II diabetes, it is a civilization disease, we challenge it with new drugs in the hope of full success. The BRG Center hopes to participate in many such Polish projects.

Go back

News

New article about EMA guidelines on FIH studies

In "Scientific Publications" tab you can find an interesting, new article about update of EMA guideline on strategies to identify and mitigate risks for first-in-human clinical trials

Read more …

Easter Wishes

To all our Sponsors, Vendors, Employees and Co-Workers we wish joy and happiness for the in-coming Easter!

Read more …

Annual GCP training

On 24th of March, 2018 we have organized the second annual GCP training for all our employees and co-workers.

Read more …

First phase study

We have just succesfully finished the second part of the first phase study with no Serious Adverse Events.

Read more …

Bioequivalence study

We have just finished clinical part of one of our ongoing bioequivalence Clinical Studies.

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2020 © Bio Research Group. All rights reserved.

 

scroll to top ▲